LENZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
LENZ Therapeutics Inc is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock shows weak technical indicators, mixed financial performance, and lacks significant positive catalysts to justify immediate entry. Holding off for clearer signs of growth or stability is recommended.
The technical indicators for LENZ are bearish. The MACD histogram is negative and expanding downward, the RSI is neutral at 21.502, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with S1 at 9.113 and S2 at 8.137, indicating potential further downside.
The company has a strong gross margin of 73.68% and a successful marketing campaign for its VIZZ product, which has driven sales exceeding 45,000 boxes. Analysts maintain a Buy rating despite lowered price targets.
The company reported a significant Q4 loss of $1.16 per share, missed revenue expectations, and has a declining price trend. Analysts have lowered price targets significantly, and the stock has experienced a selloff due to concerns about future profitability.
In Q4 2025, LENZ reported revenue of $1.59 million, flat YoY. Net income improved to -$35.9 million, up 183.72% YoY, and EPS increased to -1.15, up 150% YoY. While the gross margin is strong at 73.68%, the company is still far from profitability.
Analysts maintain a Buy rating but have significantly lowered price targets. Citi reduced its target from $52 to $26, and BofA lowered its target from $35 to $29, citing slower VIZZ product ramp-up and reduced revenue forecasts.
